oncology

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
Maha Mamoor, Michael A Postow, Jessica A Lavery, Shrujal S Baxi, Niloufer Khan, Jun J Mao, Lauren J Rogak, Robert Sidlow, Bridgette Thom, Jedd A Wolchok, Deborah Korenstein

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000260; DOI: 10.1136/jitc-2019-000260
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Flora Mulkey, Marc R Theoret, Patricia Keegan, Richard Pazdur, Rajeshwari Sridhara

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000146; DOI: 10.1136/jitc-2019-000146
CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
Feng Li, Yuqiao Sheng, Weizhou Hou, Padma Sampath, Daniel Byrd, Stephen Thorne, Yi Zhang

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000131; DOI: 10.1136/jitc-2019-000131
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
Natalia Maximova, Alessandra Maestro, Davide Zanon, Annalisa Marcuzzi

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000388; DOI: 10.1136/jitc-2019-000388
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
Ami N Shah, Lisa Flaum, Irene Helenowski, Cesar A Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000173; DOI: 10.1136/jitc-2019-000173
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
Taiki Kurino, Reiko Matsuda, Ayu Terui, Hiroyuki Suzuki, Tomomi Kokubo, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka, Hiroto Hatakeyama

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000400; DOI: 10.1136/jitc-2019-000400
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
Jie Sun, Zicheng Zhang, Siqi Bao, Congcong Yan, Ping Hou, Nan Wu, Jianzhong Su, Liangde Xu, Meng Zhou

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000110; DOI: 10.1136/jitc-2019-000110
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
Esther Lutgens, Tom T.P. Seijkens

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000300; DOI: 10.1136/jitc-2019-000300
High-dimensional immune-profiling in cancer: implications for immunotherapy
Samuel Chuah, Valerie Chew

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000363; DOI: 10.1136/jitc-2019-000363
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
Sara Pai, David Blaisdell, Rachel Brodie, Robert Carlson, Heidi Finnes, Michele Galioto, Roxanne E Jensen, Tom Valuck, Antonia R Sepulveda, Howard L Kaufman

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000112; DOI: 10.1136/jitc-2019-000112

Main menu

oncology

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

oncology

Pages